Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241497 | 0.82 | DPP4 (0.36) | DPP4 | |
| SCHEMBL3766237 | 0.81 | DPP4 (0.39) | DPP4 | |
| SCHEMBL8409023 | 0.78 | CA1 (0.36) | DPP4CA1CA2 | |
| SCHEMBL1336381 | 0.77 | DPP4 (0.36) | DPP4 | |
| SCHEMBL25101420 | 0.75 | DPP4 (0.35) | DPP4 | |
| Bicarbonate SCHEMBL11385004 | 0.75 | DPP4 (0.35) | DPP4 | |
| SCHEMBL5516754 | 0.75 | DPP4 (0.35) | DPP4 | |
| SCHEMBL9534650 | 0.74 | MCL1 (0.32) | DPP4CA1CA2 | |
| SCHEMBL9534655 | 0.73 | HMGCR (0.40) | — | |
| SCHEMBL8049516 | 0.70 | DPP4 (0.34) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505766-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150045343-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2558099-A2 | KINASE INHIBITORS | The Regents Of The University Of California, San Francisco (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035325-A1 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2011060440-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | WO | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. | 2009-09-24 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| EP-0812822-B1 | Process for the preparation of aminoacetic acids substituted at position alpha by a tertiary hydrocarbon chain or their nitriles | HUELS CHEMISCHE WERKE AG (DE) | 1999-07-28 | — | — | EP | disclosed |
| US-5831119-A | Process for the preparation of aminoacetic acids with a tertiary hydrocarbon radical in the α-position, or their nitriles | HUELS AKTIENGESELLSCHAFT (DE) | 1998-11-03 | — | — | US | disclosed |
| EP-0812822-A2 | Process for the preparation of aminoacetic acids substituted at position alpha by a tertiary hydrocarbon chain or their nitriles | HÜLS AKTIENGESELLSCHAFT (DE) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318492-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G4A, PLA2G1B, PLA2G4B | DPP4 234/4885CA1 1031/4885CA2 574/4885 |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | DPP4 181/4885CA1 3746/4885CA2 1894/4885 |
| US-20090239896-A1 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G5, PLA2G4A, PLA2G3 | DPP4 564/4885CA1 764/4885CA2 922/4885 |
| US-20130035325-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | DPP4 3315/4885CA1 4551/4885CA2 4264/4885 |
| US-20150045343-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K8 | DPP4 3315/4885CA1 4551/4885CA2 4264/4885 |
| US-20070135383-A1 | Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors | PNLIP, PLA2G2E, PLA2G3 | DPP4 99/4885CA1 1335/4885CA2 608/4885 |
| US-20090306171-A1 | INDOLE COMPOUNDS HAVING C4-AMIDE SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | PLA2G1B, PLA2G2E, PLA2G4A | DPP4 321/4885CA1 1412/4885CA2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.